Low-dose aspirin and survival from lung cancer: a population-based cohort study

BMC Cancer

Table 5 Sensitivity analyses for association between low-dose aspirin use and cancer-specific mortality in lung cancer patients

	Cancer-specific deaths	All patients	Person years	Unadjusted		P	Adjusted^a		P
				HR	95 % CI		HR	95 % CI
Main analysis: Pre-diagnostic aspirin use^b	10,632	13,433	12,485	1.07	1.02, 1.11	<0.01	1.00	0.95, 1.05	0.91
Subgroup analyses
Male	6,298	7,941	7,103	1.02	0.97, 1.08	0.44	0.98	0.91–1.04	0.46
Female	4,334	5,492	5,381	1.13	1.06–1.21	<0.001	1.03	0.95–1.11	0.53
Sensitivity analyses
Smoking prior to diagnosis available (and adjusted for)	9,560	12,063	11,336	1.07	1.03–1.12	<0.01	1.00	0.95–1.05	0.93
BMI prior to diagnosis available (and adjusted for)	8,562	10,831	10,448	1.07	1.02–1.12	<0.01	0.99	0.94–1.05	0.73
Aspirin use between 2 years and 6 months prior to diagnosis^c	9,746	12,295	11,418	1.06	1.01–1.11	0.01	0.99	0.94–1.05	0.76

^aExcept where otherwise stated, adjusted for year of diagnosis, age at diagnosis, gender, comorbidities (prior to diagnosis, including cerebrovascular disease, chronic pulmonary disease, congestive heart disease, diabetes, myocardial infarction, peptic ulcer disease, peripheral vascular disease, renal disease), other medication use (in year prior to diagnosis, specifically statins and beta-blockers) and deprivation (in fifths)
^bBased upon use in the year prior to diagnosis, restricted to individuals with 1 year of records prior to lung cancer diagnosis
^cRestricted to individuals with 2 years of records prior to diagnosis, removing prescriptions in the 6 months prior to lung cancer diagnosis as these could reflect increased medical care due to early symptoms

ISSN: 1471-2407